Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ID1-H51H8 | Human | Human IDH1 (R132C) Protein, His Tag (MALS verified) |  |
|
|
| ID1-H51H6 | Human | Human IDH1 Protein, His Tag (active enzyme, MALS verified) |  |
|
The purity of Human IDH1 (R132C), His Tag (Cat. No. ID1-H51H8) is more than 85% and the molecular weight of this protein is around 85-100 kDa verified by SEC-MALS.
The purity of Human IDH1, His Tag (Cat. No. ID1-H51H6) is more than 85% and the molecular weight of this protein is around 90-100 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ivosidenib | AG-120; CS-3010; S-95031; CS 3010 | Approved | Agios Pharmaceuticals Inc | Tibsovo, 拓舒沃, Tidhesco, Tuoshuvo, TIBSOVO, Tosuvo | United States | Leukemia, Myeloid, Acute | Servier Pharmaceuticals Llc | 2018-07-20 | Histiocytosis, Langerhans-Cell; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Lymphoma, Non-Hodgkin; Neoplasms, Neuroepithelial; Glioma; Leukemia, Myeloid, Acute; Bile Duct Neoplasms; Hepatic Insufficiency; Osteosarcoma; Sarcoma, Ewing; Cholangiocarcinoma; Pancytopenia; Sarcoma; Neuroblastoma; Ependymoma; Wilms Tumor; Sarcoma, Myeloid; Myelodysplastic Syndromes; Myeloproliferative Disorders; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Rhabdomyosarcoma; Medulloblastoma; Chondrosarcoma; Hematologic Neoplasms; Leukemia; Leukemia, Myeloid | Details |
| Olutasidenib | FT-2102 | Approved | Forma Therapeutics Holdings Inc | Rezlidhia | United States | Leukemia, Myeloid, Acute | Rigel Pharmaceuticals Inc | 2022-12-01 | Chondrosarcoma; Leukemia, Promyelocytic, Acute; Irritable Bowel Syndrome; Myelodysplastic Syndromes; Diarrhea; Leukemia, Myeloid, Acute | Details |
| Ivosidenib | AG-120; CS-3010; S-95031; CS 3010 | Approved | Agios Pharmaceuticals Inc | Tibsovo, 拓舒沃, Tidhesco, Tuoshuvo, TIBSOVO, Tosuvo | United States | Leukemia, Myeloid, Acute | Servier Pharmaceuticals Llc | 2018-07-20 | Histiocytosis, Langerhans-Cell; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Lymphoma, Non-Hodgkin; Neoplasms, Neuroepithelial; Glioma; Leukemia, Myeloid, Acute; Bile Duct Neoplasms; Hepatic Insufficiency; Osteosarcoma; Sarcoma, Ewing; Cholangiocarcinoma; Pancytopenia; Sarcoma; Neuroblastoma; Ependymoma; Wilms Tumor; Sarcoma, Myeloid; Myelodysplastic Syndromes; Myeloproliferative Disorders; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Rhabdomyosarcoma; Medulloblastoma; Chondrosarcoma; Hematologic Neoplasms; Leukemia; Leukemia, Myeloid | Details |
| Olutasidenib | FT-2102 | Approved | Forma Therapeutics Holdings Inc | Rezlidhia | United States | Leukemia, Myeloid, Acute | Rigel Pharmaceuticals Inc | 2022-12-01 | Chondrosarcoma; Leukemia, Promyelocytic, Acute; Irritable Bowel Syndrome; Myelodysplastic Syndromes; Diarrhea; Leukemia, Myeloid, Acute | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| HMPL-306 | HMPL-306 | Phase 3 Clinical | Hutchison Medipharma Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
| TQB-3454 | TQB-3454; CT-2755 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Hematologic Neoplasms; Solid tumours; Biliary Tract Neoplasms; Myelodysplastic Syndromes; Bile Duct Neoplasms; Leukemia, Myeloid, Acute | Details |
| Vorasidenib (Servier) | AGI-23088; S-95032; S95032; AG-881 | Phase 3 Clinical | Agios Pharmaceuticals Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Astrocytoma; Hepatic Insufficiency; Glioma; Leukemia, Myeloid, Acute | Details |
| Safusidenib | DS-1001b; DS-1001; AB-218 | Phase 2 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Biliary Tract Neoplasms; Glioma | Details |
| BAY-1436032 | BAY-1436032 | Phase 1 Clinical | Bayer AG | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
| TQB-3455 | TQB-3455; CT-2426 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
| IDH-305 | IDH-305 | Phase 1 Clinical | Novartis Pharma Ag | Neoplasms; Leukemia, Myeloid, Acute; Glioma | Details |
| BPI-221351 | BPI-221351 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Glioma | Details |
| KY-100001 | KY-100001 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Solid tumours | Details |
| HH-2301 | HH-2301; HH2301 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd | Biliary Tract Neoplasms; Solid tumours; Chondrosarcoma; Glioma | Details |
| LY-3410738 | LY-3410738 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Chondrosarcoma; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Myeloproliferative Disorders; Cholangiocarcinoma; Leukemia, Myeloid, Acute; Glioma | Details |
| HMPL-306 | HMPL-306 | Phase 3 Clinical | Hutchison Medipharma Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
| TQB-3454 | TQB-3454; CT-2755 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Hematologic Neoplasms; Solid tumours; Biliary Tract Neoplasms; Myelodysplastic Syndromes; Bile Duct Neoplasms; Leukemia, Myeloid, Acute | Details |
| Vorasidenib (Servier) | AGI-23088; S-95032; S95032; AG-881 | Phase 3 Clinical | Agios Pharmaceuticals Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Astrocytoma; Hepatic Insufficiency; Glioma; Leukemia, Myeloid, Acute | Details |
| Safusidenib | DS-1001b; DS-1001; AB-218 | Phase 2 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Biliary Tract Neoplasms; Glioma | Details |
| BAY-1436032 | BAY-1436032 | Phase 1 Clinical | Bayer AG | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
| TQB-3455 | TQB-3455; CT-2426 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
| IDH-305 | IDH-305 | Phase 1 Clinical | Novartis Pharma Ag | Neoplasms; Leukemia, Myeloid, Acute; Glioma | Details |
| BPI-221351 | BPI-221351 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours; Glioma | Details |
| KY-100001 | KY-100001 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Solid tumours | Details |
| HH-2301 | HH-2301; HH2301 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd | Biliary Tract Neoplasms; Solid tumours; Chondrosarcoma; Glioma | Details |
| LY-3410738 | LY-3410738 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours; Chondrosarcoma; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Myeloproliferative Disorders; Cholangiocarcinoma; Leukemia, Myeloid, Acute; Glioma | Details |
This web search service is supported by Google Inc.
A-Z
